Parkinson's Disease Autonomic Dysfunction Treatment Companies
Overview
flowchart TD
companies_pd_autonomic_dysfunc["PD Autonomic Dysfunction Treatment Companies"]
companies_pd_autonomic_dysfunc["Parkinson"]
companies_pd_autonomic_dysfunc -->|"related to"| companies_pd_autonomic_dysfunc
style companies_pd_autonomic_dysfunc fill:#81c784,stroke:#333,color:#000
companies_pd_autonomic_dysfunc["Treatment"]
companies_pd_autonomic_dysfunc -->|"related to"| companies_pd_autonomic_dysfunc
style companies_pd_autonomic_dysfunc fill:#81c784,stroke:#333,color:#000
companies_pd_autonomic_dysfunc["most"]
companies_pd_autonomic_dysfunc -->|"related to"| companies_pd_autonomic_dysfunc
style companies_pd_autonomic_dysfunc fill:#81c784,stroke:#333,color:#000
companies_pd_autonomic_dysfunc["debilitating"]
companies_pd_autonomic_dysfunc -->|"related to"| companies_pd_autonomic_dysfunc
style companies_pd_autonomic_dysfunc fill:#81c784,stroke:#333,color:#000
style companies_pd_autonomic_dysfunc fill:#4fc3f7,stroke:#333,color:#000
Autonomic dysfunction is one of the most debilitating non-motor symptoms of [Parkinson's disease](/diseases/parkinsons-disease), affecting up to 50% of patients and significantly impacting quality of life. The autonomic nervous system controls involuntary functions including blood pressure, heart rate, digestion, bladder function, and sleep. In PD, neurodegeneration extends beyond dopaminergic neurons to affect autonomic pathways, leading to multiple complications["@pd-autonomic-review"].
...Parkinson's Disease Autonomic Dysfunction Treatment Companies
Overview
Mermaid diagram (expand to render)
Autonomic dysfunction is one of the most debilitating non-motor symptoms of [Parkinson's disease](/diseases/parkinsons-disease), affecting up to 50% of patients and significantly impacting quality of life. The autonomic nervous system controls involuntary functions including blood pressure, heart rate, digestion, bladder function, and sleep. In PD, neurodegeneration extends beyond dopaminergic neurons to affect autonomic pathways, leading to multiple complications["@pd-autonomic-review"].
This page catalogs pharmaceutical and biotechnology companies developing treatments for the various manifestations of autonomic dysfunction in Parkinson's disease.
Types of Autonomic Dysfunction in PD
Orthostatic Hypotension
Orthostatic hypotension (OH) is a drop in blood pressure upon standing, causing dizziness, syncope, and falls. It results from sympathetic noradrenergic denervation and impaired baroreflex function[@oh-treatment].
Key Treatments:
- Midodrine — alpha-1 agonist (available)
- Droxidopa — norepinephrine prodrug (available)
- Pyridostigime — acetylcholinesterase inhibitor
Gastrointestinal Dysfunction
GI dysfunction includes delayed gastric emptying (gastroparesis), constipation, and small intestinal bacterial overgrowth. This results from enteric nervous system involvement and vagal nerve degeneration[@gi-dysfunction-pd].
Key Treatments:
- Prokinetic agents (metoclopramide, domperidone)
- Laxatives and stool softeners
- Antibiotics for SIBO
Urinary Dysfunction
Urinary symptoms include urgency, frequency, nocturia, and in severe cases, retention. These result from detrusor overactivity and impaired sphincter coordination.
Key Treatments:
- Anticholinergics (solifenacin, tolterodine)
- Beta-3 agonists (mirabegron)
- Alpha-blockers (tamsulosin)
Sleep Disorders
REM sleep behavior disorder (RBD), insomnia, and sleep fragmentation are common in PD. These may precede motor symptoms by years.
Key Treatments:
- Melatonin
- Clonazepam
- Modafinil for excessive daytime sleepiness
Companies Developing PD Autonomic Treatments
AbbVie
[AbbVie](/companies/abbvie) is a major pharmaceutical company with a broad neuroscience portfolio including treatments relevant to PD autonomic dysfunction.
Relevant Programs:
| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| Duodopa/Duopa | Advanced PD motor symptoms | Continuous levodopa infusion | Approved |
| ABBV-951 | Advanced PD | Fos-levodopa/carbidopa subcutaneous infusion | Approved |
| Neuraly Partnership | PD (NLY01 GLP-1R agonist) | Neuroprotection | Phase 2 |
Autonomic Relevance:
- ABBV-951 continuous delivery may help stabilize blood pressure fluctuations
- NLY01 GLP-1R agonist may protect autonomic neurons
- Their PD treatments address motor symptoms that can worsen autonomic function
Sunovion
[Sunovion](/companies/sunovion) (a Sumitomo Pharma company) focuses on CNS disorders including Parkinson's disease.
Relevant Programs:
| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| Apomorphine (Apokyn) | PD OFF episodes | Dopamine agonist (injectable) | Approved |
| Apomorphine SL | PD OFF episodes | Rapid-onset sublingual | Phase 3 |
| ABBV-951 | Advanced PD | Continuous subcutaneous infusion | Approved |
Autonomic Relevance:
- Apomorphine provides rapid rescue from OFF episodes, potentially reducing autonomic stress
- Their focus on continuous dopaminergic stimulation may improve autonomic stability
Supernus Pharmaceuticals
[Supernus Pharmaceuticals](/companies/supernus-pharmaceuticals) has an expanding Parkinson's disease portfolio.
Relevant Programs:
| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| APOKYN | PD OFF episodes | Apomorphine injection | Approved |
| SPN-830 | Advanced PD | Apomorphine continuous infusion | Phase 3 |
Autonomic Relevance:
- SPN-830 continuous apomorphine infusion may help maintain stable dopaminergic stimulation, potentially benefiting autonomic function
- Their ADHD portfolio includes treatments for sleep disorders (Qelbree/viloxazine)
Intellia Therapeutics
[Intellia](/companies/intellia) is pioneering in vivo CRISPR gene editing.
Relevant Programs:
| Program | Indication | Target | Status |
|---------|------------|--------|--------|
| NTLA-2001 | ATTR amyloidosis | TTR gene knockout | Phase 3 |
| Neurological programs | ALS, AD, PD | Various | Discovery |
Autonomic Relevance:
- While not directly targeting PD autonomic dysfunction, their gene therapy platform could eventually address genetic forms of autonomic neuropathy
- ATTR amyloidosis has significant autonomic manifestations, providing relevant expertise
- Their partnership with Regeneron focuses on neurological diseases including PD
Takeda Pharmaceutical
[Takeda](/companies/takeda) has a significant neuroscience pipeline with relevance to PD.
Relevant Programs:
| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| T-052 | PD | Alpha-synuclein aggregation inhibitor | Phase 1 |
| T-345 | PD | LRRK2 kinase inhibitor | Phase 1 |
| T-817MA | AD | Neuroprotective agent | Phase 2 |
Autonomic Relevance:
- T-345 LRRK2 inhibitor may protect autonomic neurons
- Takeda's rare disease expertise (including ATTR) provides relevant knowledge for autonomic dysfunction
- Their neuroprotective approach could benefit autonomic pathways
Lundbeck
[Lundbeck](/companies/lundbeck) is a Danish neuroscience-focused pharmaceutical company that acquired droxidopa (brand name Northera) from NeuroMedix in 2016, expanding their Parkinson's disease portfolio to include treatment for autonomic dysfunction.
Relevant Programs:
| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| Droxidopa (Northera) | Neurogenic orthostatic hypotension | Norepinephrine prodrug | Approved (FDA) |
| Lu AG06466 | Parkinson's disease | Alpha-synuclein modulator | Phase 1 |
| Ongentys (opicapone) | Parkinson's disease | COMT inhibitor | Approved |
Autonomic Relevance:
- Droxidopa is one of only three FDA-approved treatments for orthostatic hypotension
- Addresses neurogenic orthostatic hypotension (nOH) which affects 30-50% of PD patients
- Works by increasing norepinephrine levels to compensate for sympathetic nervous system dysfunction
- The acquisition of Northera positioned Lundbeck as a leader in PD autonomic dysfunction treatment
Emerging Research Areas
GLP-1 Receptor Agonists
[Neuraly](/companies/neuraly)'s NLY01 and similar GLP-1R agonists are being investigated for neuroprotective effects in PD. These agents may protect autonomic neurons through anti-inflammatory and anti-apoptotic mechanisms.
Alpha-Synuclein Targeting
Companies like [Prothena](/companies/prothena), [Vaxxinity](/companies/vaxxinity), and others are developing treatments targeting alpha-synuclein. Since autonomic dysfunction is driven by alpha-synuclein pathology in the peripheral and central autonomic nervous system, these approaches may address the root cause.
Gene Therapy Approaches
Gene therapy companies including [UniQure](/companies/uniqure), [Prevail Therapeutics](/companies/prevail-therapeutics), and others are developing AAV-based treatments that could potentially target autonomic neurons.
Clinical Trial Landscape
Active Trials in PD Autonomic Dysfunction
| Trial | Company | Treatment | Indication | Phase |
|-------|---------|-----------|------------|-------|
| NCT05431240 | AbbVie | ABBV-951 | Advanced PD (OFF time) | Phase 3 |
| NCT05359851 | Supernus | SPN-830 | Advanced PD (apomorphine infusion) | Phase 3 |
| NCT05024240 | Neuraly | NLY01 | Early PD | Phase 2 |
Related Pages
Disease and Mechanism Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Autonomic Dysfunction in Corticobasal Syndrome](/diseases/autonomic-dysfunction-in-corticobasal-syndrome)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
- [Noradrenergic Signaling](/mechanisms/norepinephrine-signaling)
- [Autonomic Nervous System](/entities/autonomic-nervous-system)
Treatment Pages
- [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
- [Parkinson's Non-Motor Symptoms](/therapeutics/parkinsons-non-motor-symptoms)
- [Dopamine Agonists](/therapeutics/dopamine-agonists)
Company Pages
- [PD Pipeline Companies](/companies/pd-pipeline-companies)
- [AbbVie](/companies/abbvie)
- [Sunovion](/companies/sunovion)
- [Supernus Pharmaceuticals](/companies/supernus-pharmaceuticals)
- [Intellia](/companies/intellia)
- [Takeda](/companies/takeda)
- [Neuraly](/companies/neuraly)
References
[Singer W, et al., Autonomic dysfunction in Parkinson disease, Nat Rev Neurol (2023)](https://doi.org/10.1038/s41582-023-00819-4)
[Gibbons CH, et al., Orthostatic hypotension in neurodegenerative disease, Clin Auton Res (2019)](https://pubmed.ncbi.nlm.nih.gov/30655302/)
[Fasano A, et al., Gastrointestinal dysfunction in Parkinson's disease, Lancet Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/25998083/)Pathway Diagram
The following diagram shows the key molecular relationships involving PD Autonomic Dysfunction Treatment Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)